



Funder	COVID-19 Funding	Process Changes
Astellas	Nothing currently.	Not accepting IME grants involving live, in-person events until further notice. An exception will be granted for ASH satellite symposia requests, due to the application deadline of May 29th, 2020 . For all enduring grant submissions, include a contingency plan should travel be restricted.
Boehringer Ingelheim Pharmaceuticals, Inc	Nothing currently.	BIPI has announced flexibility as reasonably possible with timelines (start/end date), program format, reports and other affected obligations written in current LOAs. It is highly encouraged that any new grant submissions with a start date prior to September 1, 2020 , only include virtual or print components. BIPI will evaluate every grant impacted on a case-by-case basis.
Genentech	Nothing currently.	Contact give@gene.com if program is already funded.
Novartis	COVID-19 submissions will be accepted for a period of 4 weeks ending April 30, 2020 , after which submissions in this area will undergo a comprehensive review process. Decisions will be communicated shortly thereafter via the grants system.	Novartis will temporarily suspend the requirement for the request to be submitted at least 60 days prior to the activity Start Date.
Pfizer	Nothing currently.	Expect delays in grant processing. They are reaching out to grantees individually.

Please Note: Many funders are not accepting applications for in-person trainings in the midst of the COVID-19 pandemic. Overall, funders are asking for as much communication as possible with regards to rescope activities affected by COVID-19 (postponement, rescheduling, reformatting, etc.).